Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2016

The Pharma Closeout tracks 141 deals, $511.9B in disclosed deal value, 52 with a post-close Outcome Score for the year 2016.

Median Critic Score: 75  ·  Median Outcome Score: 36

Best outcome: AbbVie Inc. / Boehringer Ingelheim GmbH (95)  ·  Weakest outcome: AbbVie Inc. / Stemcentrx Inc. (9)

All 141 deals

• AbbVie Inc. / Boehringer Ingelheim GmbH — 2016 · $2.2B · Worked — the deal delivered on its rationale.
• Abbott Laboratories / Alere Inc. — 2016 · $5.8B · Worked — the deal delivered on its rationale.
• Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. — 2016 · $17.6B · Worked — the deal delivered on its rationale.
• Shire plc / Dyax Corp. — 2016 · $5.9B · Worked — the deal delivered on its rationale.
• Pfizer Inc. / Medivation Inc. — 2016 · $14.0B · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / Moderna, Inc. — 2016 · $250M · Worked — the deal delivered on its rationale.
• Sanofi S.A. / Boehringer Ingelheim GmbH (consumer healthcare business swap) — 2016 · $25.1B · Worked — the deal delivered on its rationale.
• Abbott Laboratories / St. Jude Medical — 2016 · $30.5B · Worked — the deal delivered on its rationale.
• Astellas Pharma Inc. / Ganymed Pharmaceuticals — 2016 · $1.4B · Worked — the deal delivered on its rationale.
• LEO Pharma A/S / AstraZeneca PLC — 2016 · $1.1B · Worked — the deal delivered on its rationale.
• Ipsen S.A. / Exelixis Inc. — 2016 · $855M · Worked — the deal delivered on its rationale.
• Shire plc / Baxalta Inc. — 2016 · $32.0B · Worked — the deal delivered on its rationale.
• Abbott Laboratories / St. Jude Medical — 2016 · $25.0B · Worked — the deal delivered on its rationale.
• Jazz Pharmaceuticals PLC / Celator Pharmaceuticals — 2016 · $1.5B · Largely worked — most objectives met.
• AstraZeneca PLC / Aspen Global Inc. (Aspen Pharmacare) — 2016 · $770M · Largely worked — most objectives met.
• Novo Holdings A/S / Catalent, Inc. — 2016 · $16.5B · Largely worked — most objectives met.
• Johnson & Johnson / Abbott Laboratories (Abbott Medical Optics) — 2016 · $4.3B · Largely worked — most objectives met.
• Mylan N.V. / Meda AB — 2016 · $9.9B · Mixed — partial payoff, real shortfalls.
• ICU Medical, Inc. / Pfizer Inc. (Hospira Infusion Systems business) — 2016 · $1.0B · Mixed — partial payoff, real shortfalls.
• AbbVie Inc. / Synlogic — 2016 · $18M · Mixed — partial payoff, real shortfalls.
• Horizon Pharma plc / Raptor Pharmaceutical Corp. — 2016 · $860M · Mixed — partial payoff, real shortfalls.
• Lonza Group AG / Capsugel S.A. — 2016 · $5.5B · Underwhelmed — fell short of the thesis.
• Pfizer Inc. / Anacor Pharmaceuticals — 2016 · $5.2B · Underwhelmed — fell short of the thesis.
• Mylan N.V. / Renaissance Acquisition Holdings, LLC (topicals business) — 2016 · $1.0B · Underwhelmed — fell short of the thesis.
• Lonza Group AG / Capsugel S.A. (KKR portfolio) — 2016 · $5.5B · Underwhelmed — fell short of the thesis.
• Novartis AG / Selexys Pharmaceuticals — 2016 · $665M · Underwhelmed — fell short of the thesis.
• AstraZeneca PLC / Pfizer Inc. — 2016 · $1.6B · Underwhelmed — fell short of the thesis.
• Bayer AG / Monsanto Company — 2016 · $63.0B · Underwhelmed — fell short of the thesis.
• Celgene Corporation / Jounce Therapeutics Inc. — 2016 · $2.7B · Did not work — the deal failed to deliver.
• Sumitomo Dainippon Pharma Co., Ltd. / Cynapsus Therapeutics Inc. — 2016 · $624M · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Padlock Therapeutics, Inc. — 2016 · $600M · Did not work — the deal failed to deliver.
• Novartis AG / Ionis Pharmaceuticals, Inc. / Akcea Therapeutics, Inc. — 2016 · $1.4B · Did not work — the deal failed to deliver.
• AbbVie Inc. / argenx SE — 2016 · $685M · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Cormorant Pharmaceuticals AB — 2016 · $520M · Did not work — the deal failed to deliver.
• Sumitomo Dainippon Pharma Co., Ltd. / Tolero Pharmaceuticals, Inc. — 2016 · $780M · Did not work — the deal failed to deliver.
• Teva Pharmaceutical Industries Ltd. / Allergan plc (Actavis Generics business) — 2016 · $40.5B · Did not work — the deal failed to deliver.
• Merck & Co., Inc. / IOmet Pharma Ltd. — 2016 · $400M · Did not work — the deal failed to deliver.
• Merck & Co., Inc. / Afferent Pharmaceuticals, Inc. — 2016 · $1.2B · Did not work — the deal failed to deliver.
• Gilead Sciences Inc. / Nimbus Apollo, Inc. (Nimbus Therapeutics subsidiary) — 2016 · $1.2B · Did not work — the deal failed to deliver.
• Teva Pharmaceutical Industries Ltd. / Allergan plc (Anda Inc.) — 2016 · $500M · Did not work — the deal failed to deliver.
• F. Hoffmann-La Roche AG / Tensha Therapeutics, Inc. — 2016 · $535M · Did not work — the deal failed to deliver.
• Allergan plc / Anterios, Inc. — 2016 · $90M · Did not work — the deal failed to deliver.
• Gilead Sciences Inc. / Galapagos NV — 2016 · $2.1B · Did not work — the deal failed to deliver.
• Allergan plc / Topokine Therapeutics, Inc. — 2016 · $85M · Did not work — the deal failed to deliver.
• Allergan plc / Tobira Therapeutics, Inc. — 2016 · $1.7B · Did not work — the deal failed to deliver.
• Allergan plc / ForSight VISION5, Inc. — 2016 · $95M · Did not work — the deal failed to deliver.
• Adaptimmune Therapeutics plc / GlaxoSmithKline plc — 2016 · $500M · Did not work — the deal failed to deliver.
• Allergan plc / Vitae Pharmaceuticals, Inc. — 2016 · $639M · Did not work — the deal failed to deliver.
• Pfizer Inc. / Bamboo Therapeutics, Inc. — 2016 · $645M · Did not work — the deal failed to deliver.
• Allergan plc / Heptares Therapeutics Ltd. — 2016 · $790M · Did not work — the deal failed to deliver.
• Novartis AG / Ziarco Group Limited — 2016 · $420M · Did not work — the deal failed to deliver.
• AbbVie Inc. / Stemcentrx Inc. — 2016 · $9.8B · Did not work — the deal failed to deliver.
• Asahi Kasei Pharma / Array BioPharma — 2016
• Vifor Pharma / ChemoCentryx — 2016
• Avalanche Biotechnologies / Annapurna Therapeutics — 2016
• Amgen / Nuevolution — 2016
• Checkpoint Therapeutics / Jubilant Biosys — 2016
• Checkpoint Therapeutics / Teva Pharmaceutical Industries — 2016
• Pfizer Inc. / Allergan plc — 2016 · $160.0B
• AiVita Biomedical / Caladrius Biosciences — 2016
• Immune Design / Gritstone Oncology — 2016
• Amgen / Janssen Biotech — 2016
• Novartis / Surface Oncology — 2016
• Chugai Pharmaceutical / PharmaMar — 2016
• Spero Therapeutics / Promiliad Biopharma — 2016
• Almirall / Sun Pharma — 2016
• Wanbang Biopharmaceutical / Rockwell Medical — 2016 · $39M
• Mylan / Momenta Pharmaceuticals — 2016
• PCI Biotech / Ultimovacs — 2016
• Takeda Pharmaceutical Company / EnGeneIC — 2016
• Sanofi / Innate Pharma — 2016
• KemPharm / Acura Pharmaceuticals — 2016
• Irx Therapeutics / ImmunID — 2016
• Novartis / Conatus Pharmaceuticals — 2016
• iTeos Therapeutics / Cristal Therapeutics — 2016
• Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. — 2016 · $910M
• Akari Therapeutics / XL-protein — 2016
• Watson Laboratories / Adamis Pharmaceuticals — 2016 · $32M
• Upsher-Smith Laboratories / Saniona — 2016
• Boehringer Ingelheim / ViraTherapeutics — 2016
• NeoTX Therapeutics / Active Biotech — 2016 · $71M
• Emergex Vaccines / Midatech Pharma — 2016
• Capnia / Essentialis — 2016
• Celgene / Triphase Accelerator — 2016
• Cell Care Therapeutics / TheraKine — 2016
• Green Cross LabCell / OGD2 Pharma — 2016
• Monvida Pharmaceuticals / Cloaked Therapeutics — 2016
• AbbVie / CytomX Therapeutics — 2016
• Amgen / Arrowhead Pharmaceuticals — 2016
• Eli Lilly / Athenex — 2016
• Knight Therapeutics / AstraZeneca — 2016
• Asahi Kasei Pharma / Basilea Pharmaceutica — 2016
• Ono Pharmaceutical / Celyad — 2016
• Bristol Myers Squibb / Calithera Biosciences — 2016
• Allergan / UroGen Pharma — 2016
• Sanofi / Dice Molecules — 2016
• ProMetic Life Sciences / Telesta Therapeutics — 2016
• Novartis / Xencor — 2016
• Eli Lilly / Boehringer Ingelheim — 2016
• Sucampo Pharmaceuticals / Cancer Prevention Pharmaceuticals — 2016
• Hanmi Pharmaceutical Co. Ltd. / Boehringer Ingelheim GmbH — 2016 · $730M
• Thera Neuropharma / RXi Pharmaceuticals — 2016
• Spring Bank Pharmaceuticals / Arbutus Biopharma — 2016
• Eisai / Huya Bioscience International — 2016 · $280M
• Takeda / TiGenix — 2016
• Cosmo Technologies / PAION — 2016
• Takeda Pharmaceutical / Arcturus Therapeutics — 2016
• MedImmune / Cepheid — 2016
• Janssen Biotech, Inc. (Johnson & Johnson) / MacroGenics, Inc. — 2016 · $740M
• Regeneron Pharmaceuticals / Adicet Bio — 2016
• Valeant Pharmaceuticals / Norgine — 2016
• AstraZeneca PLC / Allergan plc — 2016 · $1.5B
• Sotio / NBE Therapeutics — 2016
• QLT / Aegerion Pharmaceuticals — 2016
• Bayer / DelSiTech — 2016
• Merck & Co. / Adaptimmune Therapeutics — 2016
• Bristol Myers Squibb / Enterome — 2016
• Vaccinex / biOasis Technologies — 2016
• Tarveda Therapeutics / Madrigal Pharmaceuticals — 2016
• ARAM Medical / Rockwell Medical — 2016
• Biogen / REGENXBIO — 2016
• RXi Pharmaceuticals / MirImmune — 2016
• Advanced Proteome Therapeutics / Heidelberg Pharma — 2016
• ProNAi Therapeutics / Carna Biosciences — 2016
• Recordati / Pro Farma — 2016
• Daiichi Sankyo / Portola Pharmaceuticals — 2016
• Vivelix Pharmaceuticals / Idera Pharmaceuticals — 2016
• Dermavant Sciences / Portola Pharmaceuticals — 2016
• Takeda / Ultragenyx — 2016
• Bayer / Progenics Pharmaceuticals — 2016
• Benitec Biopharma / NantWorks — 2016
• Novogen / Genentech — 2016
• OGD2 Pharma / Syndivia — 2016
• Editas Medicine / Adverum Biotechnologies — 2016
• Verastem / Infinity Pharmaceuticals — 2016
• Sarepta Therapeutics / Summit Therapeutics — 2016
• Torii Pharmaceutical / Menlo Therapeutics — 2016
• Adaptimmune Therapeutics / Bellicum Pharmaceuticals — 2016
• Healios / Athersys — 2016
• Elsalys Biotech / Transgene — 2016
• Emergent BioSolutions / Integrated BioTherapeutics — 2016

← Deal Library  ·  Interactive search  ·  How we score deals